Limitations, agreements, and source contact

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors · Source last updated 2022-07-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

This study was terminated early due to not meeting the primary efficacy endpoint at a pre-planned interim analysis.

point Of Contact

email

jsmith@hoosiercancer.org

organization

Hoosier Cancer Research Network

phone

317-921-2050

title

Clinical Data Coordinator

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice